CLINICAL TRIALS PROFILE FOR TROKENDI XR
✉ Email this page to a colleague
All Clinical Trials for TROKENDI XR
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03280342 ↗ | Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine | Withdrawn | Supernus Pharmaceuticals, Inc. | Phase 2 | 2017-10-30 | Crossover, randomized, double blind: Q12h dosing in both periods; matching placebo for evening dosing during XR treatment; target dose: 100mg |
NCT03280342 ↗ | Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine | Withdrawn | University of Minnesota | Phase 2 | 2017-10-30 | Crossover, randomized, double blind: Q12h dosing in both periods; matching placebo for evening dosing during XR treatment; target dose: 100mg |
NCT03280342 ↗ | Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine | Withdrawn | University of Minnesota - Clinical and Translational Science Institute | Phase 2 | 2017-10-30 | Crossover, randomized, double blind: Q12h dosing in both periods; matching placebo for evening dosing during XR treatment; target dose: 100mg |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TROKENDI XR
Condition Name
Clinical Trial Locations for TROKENDI XR
Trials by Country
Clinical Trial Progress for TROKENDI XR
Clinical Trial Phase
Clinical Trial Sponsors for TROKENDI XR
Sponsor Name